Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder-Reference-Cited by-同舟云学术

Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder

Published:2019-07-12 Issue:3 Volume:475 Page:349-356
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Rodriguez Pena Maria Del Carmen,Chaux Alcides,Eich Marie-Lisa,Tregnago Aline C.,Taheri Diana,Borhan Walaa,Sharma Rajni,Rezaei M. Katayoon,Netto George J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00428-019-02618-5.pdf

Reference18 articles.

1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551

2. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–461. https://doi.org/10.1016/j.eururo.2016.05.041

3. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920. https://doi.org/10.1016/s0140-6736(16)00561-4

4. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JA, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18:312–322. https://doi.org/10.1016/s1470-2045(17)30065-7

5. Sjodahl G, Lovgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, Aine M, Eriksson P, Mansson W, Lindgren D, Ferno M, Liedberg F, Hoglund M (2013) Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol 183:681–691. https://doi.org/10.1016/j.ajpath.2013.05.013

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunohistochemical expression of GATA3, CK5/6 and CK20 in molecular subtypes of bladder carcinoma: correlation with clinicopathological features;Bulletin of the National Research Centre;2024-08-29

2. Advances, recognition, and interpretation of molecular heterogeneity among conventional and subtype histology of urothelial carcinoma (UC): a survey among urologic pathologists and comprehensive review of the literature;Histopathology;2024-07-29

3. Expression of HER2 in urothelial carcinoma and its significance;Current Urology;2024-05-27

4. Survival and clinicopathological significance of B7-H3 in bladder cancer: a systematic review and meta-analysis;BMC Urology;2024-03-11

5. Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder;International Urology and Nephrology;2023-10-01